PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
1999 | 46 | 3 |

Tytuł artykułu

Molecular modelling of the oxytocin receptor-bioligand interactions

Warianty tytułu

Języki publikacji

EN

Abstrakty

EN
Oxytocin is a nonapeptide hormone (CYIQNCPLG-NH2, OT), controlling labor and lactation in mammalian females, via interactions with specific cellular membrane receptors (OTRs). The native hormone is cyclized via a 1-6 disulfide and its receptor belongs to the GTP-binding (G) protein-coupled receptor (GPCR) family, also known as heptahelical transmembrane (7TM) or serpentine receptors. Using a technique combining multiple sequence alignments with available experimental constraints, a reliable OTR model was built. Subsequently, the OTR complexes with a selective agonist [Thr4,Gly7]OT, a selective cyclohexapeptide antagonist L-366,948 and oxytocin itself were modeled and relaxed using a constrained simulated annealing (CSA) protocol. All three ligands seem to prefer similar modes of binding to the receptor, manifested by repeating receptor residues which directly interact with the ligands. Those involved in the three complexes are putative helices: TM3: R113, K116, Q119, M123; TM4: Q171, and TM5: I201 and T205. Most of them are the equivalent residues/positions to those found in our earlier studies, regarding related vasopressin V2 receptor/bioligand interactions.

Wydawca

-

Rocznik

Tom

46

Numer

3

Opis fizyczny

p.581-590,fig.

Twórcy

  • University of Gdansk, J.Sobieskiego 18, 80-952 Gdansk, Poland

Bibliografia

  • 1. Ji, T.M., Grossman, M. & Ji, I. (1998) G protein-coupled receptors. I. Diversity of recep-tor-ligand interactions. J. Biol. Chem. 273, 17299-17302.
  • 2. Bikker, J.A., Trumpp-Kallmeyer, S. & Hum-blet, C. (1998) G-protein coupled receptors: Models, mutagenesis, and drug design. J. Med. Chem. 41, 2911-2927.
  • 3. Baldwin, J.M. (1993) The probable arrangement of the helices in G-protein-coupled receptors. EMBOJ. 12, 1693-1703.
  • 4. Baldwin, J.M., Schettler G.F.X., & Unger, V.M. (1997) An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protem-coupled receptors. J. Mol. BioL 272, 144-164.
  • 5. Schertler, G.?.X. & Hargrave, P.A. (1995) Projection structure of frog rhodopsin in two crystal forms. Proc. Natl Acad. Scu U.S.A. 92, 11578-11582.
  • 6. Unger, V.M., Hargrave, P.A., Baldwin, J.M. & Schertler, G.F.X. (1997) Arrangement of rhodopsin transmembrane alpha helices obtained by electron cryo-microscopy Nature 389, 203-206.
  • 7. Herzyk, P. & Hubbard, R.E. (1995) Automated method for modeling seven-helix transmembrane receptors from experimental data. Biophys. J. 69, 2419-2442.
  • 8. Peitsch, M.C., Herzyk, P., Wells, T.N.C. & Hubbard, R. (1995) Automated G protein- coupled receptor modeling by Swiss-Model: URL http://expasy.hcuge.ch/8wis8mod/SWISS-MODEL.html
  • 9. Iismaa, T.P., Biden, T.J. & Shine, J. (1995) G Protein-Coupled Receptors, Chapter 1, Springer-Verlag, Heidelberg.
  • 10.Willams, P.D., Bock, M.G., Tung, R.D., Garsky, V.M., Perlow, D.S., Erb, J.M., Lundell, G.F., Gould, N.P, Whitter, W.L., Hoffman, J.B., Kauffman, M.J., Clineschmidt, B.V., Pettibone, D.J., Freidinger, R.M. & Veber, D.F. (1992) Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product. J. Med. Chern. 35, 3905-3918.
  • 11. Barberis, C. & Tribollet, E. (1996) Vasopressin and oxytocin receptors in the central nervous system. Crit. Rev. NeurobioL 10, 119-154.
  • 12. Baldwin, J.M. (1994) Structure and function of receptors coupled to G proteins. Curr. Opin. Cell Biol. 6, 180-190.
  • 13.SYBYL 6.1 (1994) Tripos Inc., 1699 S. Manley Rd., St. Louis, MO 63144, U.SA
  • 14. Czaplewski, C., Kazmierkiewicz, R. & Ciarkowski, J. (1998) Molecular modeling of the human vasopresisn V2 receptor/agonist complex. J. Comp.-Aided Molec. Design 12, 275-287.
  • 15. Chini, B., Mouillac, B., Balestre, M.-N., Trumpp-Kallmeyer, S., Hoflack, J., Hibert, M., Andriolo, M, Pupier, S., Jard, S. & Barberis, C. (1996) Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett 397, 201-206.
  • 16. Chini, B., Mouillac, B., Ala, Y., Balestre, M.-N., Trumpp-Kallmeyer, S., Moflack, J., Elands, J., Hibert, M., Manning, M., Jard, S. & Barberis, C. (1995) Tyrll5 is a key residue for determining agonist selectivity in the Via vasopressin receptor. EMBOJ. 14, 2176-2182.
  • 17. Pearlman, D.A., Case, D.A., Caidwell, J.W., Ross, W.S., Cheatham III, T.E., Ferguson D.M., Seibel, G.L., Singh, U.C., Weiner, P.K. & Kollman, P.A. (1995) AMBER, v. 4.1, University of California, San Francisco, CA, U.S.A.
  • 18. Schmidt, M.W., Baldridge, K.K., Boatz, J.A., Elbert, S.T., Gordon, M.S., Jensen, J.M, Koseki, S., Matsunaga, N., Nguyen, K.A., Su, S., Windus, T.L., Dupuis, M. & Montgomery, J.A. (1993) General atomic and molecular electronic structure system. J. CompuL Chem. 14 1347-1363.
  • 19. Bayly, C.I., Cieplak, P., Cornell, W.D. & Kollman, P. (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model. J. Phys. Chem. 97, 10269-10280.
  • 20. Koradi, R., Billeter, M. & Wuthrich, K. (1996) MOLMOL: A program for display and analysis of macromolecular structures. J. Mol Graphics 14, 51-55.
  • 21. Czaplewski, C., Kazmierkiewicz, R. & Ciarkowski, J. (1998) Molecular modeling of the vasopressin V2 receptor/antagonist interactions Acta Biochim Polon. 45, 19-29.
  • 22. Czaplewski, C., Kaimierkiewicz, R. & Ciarkowski, J. (1998) Vasopressin V2 recep-tor/bioligand interactions Lett Peptide Sri. 5, 333-335.
  • 23.Mouillac, B., Chini, B., Balestre, M.-N., Elands, J., Trumpp-Kallmeyer, S., Hoflack, J., Hibert, M., Jard, S. & Barberis, C. (1995) The binding site of neuropeptide vasopressin Via receptor. J. Biol Chem. 270, 25771-25777.

Typ dokumentu

Bibliografia

Identyfikatory

Identyfikator YADDA

bwmeta1.element.agro-article-6f768b60-394f-4ea4-aad9-68a172b42bc8
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.